SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 254 filers reported holding SAGE THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $1,159,000 | +155.8% | 7,288 | +54.2% | 0.00% | +50.0% |
| Q4 2018 | $453,000 | +6.8% | 4,726 | +57.5% | 0.00% | +100.0% |
| Q3 2018 | $424,000 | -9.8% | 3,000 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $470,000 | -6.6% | 3,000 | -4.0% | 0.00% | -50.0% |
| Q1 2018 | $503,000 | -2.7% | 3,126 | -0.4% | 0.00% | 0.0% |
| Q4 2017 | $517,000 | +108.5% | 3,140 | +0.9% | 0.00% | +100.0% |
| Q2 2017 | $248,000 | +9.3% | 3,111 | -2.8% | 0.00% | 0.0% |
| Q1 2017 | $227,000 | – | 3,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |